Profile data is unavailable for this security.
About the company
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
- Revenue in USD (TTM)6.86m
- Net income in USD-228.69m
- Incorporated2022
- Employees29.00
- LocationNewAmsterdam Pharma Company NVGooimeer 2-35NAARDEN 1411 DCNetherlandsNLD
- Phone+31 352062971
- Websitehttps://ir.newamsterdampharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.46bn | 20.00 | -- | 14.87 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 355.40m | -208.59m | 1.50bn | 536.00 | -- | -- | -- | 4.22 | -1.07 | -1.07 | 1.81 | -2.31 | 0.727 | 0.1787 | 6.51 | 663,050.40 | -42.67 | -47.95 | -54.00 | -64.89 | 98.56 | 97.06 | -58.69 | -114.94 | 3.48 | -1.00 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.52bn | 297.00 | 251.29 | 3.51 | 139.84 | 5.03 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| MannKind Corp | 224.60m | 8.49m | 1.58bn | 414.00 | 247.55 | -- | 117.43 | 7.03 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Spyre Therapeutics Inc | 688.00k | -364.23m | 1.59bn | 30.00 | -- | -- | -- | 2,317.68 | -71.35 | -71.35 | 0.0456 | 11.08 | 0.0026 | -- | -- | 22,933.33 | -134.88 | -101.87 | -150.32 | -118.83 | -- | -- | -52,939.68 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.66bn | 142.00 | -- | 3.28 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.69bn | 33.00 | -- | 11.32 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| NewAmsterdam Pharma Company NV | 6.86m | -228.69m | 1.69bn | 29.00 | -- | 4.10 | -- | 246.64 | -2.70 | -2.70 | 0.0815 | 4.59 | -- | -- | -- | 236,620.70 | -- | -- | -- | -- | -- | -- | -3,332.64 | -- | -- | -- | 0.0001 | -- | -86.28 | -- | -681.73 | -- | -- | -- |
| Keros Therapeutics Inc | 234.00k | -160.30m | 1.79bn | 141.00 | -- | 3.95 | -- | 7,668.60 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Mirum Pharmaceuticals Inc | 224.00m | -158.56m | 1.81bn | 278.00 | -- | 7.70 | -- | 8.07 | -3.82 | -3.82 | 5.19 | 4.99 | 0.4546 | 4.24 | 5.62 | 848,477.30 | -32.18 | -38.93 | -38.17 | -44.88 | 73.26 | -- | -70.79 | -190.71 | 3.47 | -- | 0.5667 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Akero Therapeutics Inc | 0.00 | -179.27m | 1.87bn | 58.00 | -- | 2.21 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -254.02m | 1.90bn | 120.00 | -- | 4.47 | -- | -- | -1.55 | -1.55 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 1.92bn | 55.00 | -- | 5.42 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
Data as of Jul 23 2024. Currency figures normalised to NewAmsterdam Pharma Company NV's reporting currency: US Dollar USD
29.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 31 Mar 2024 | 8.02m | 8.92% |
| RA Capital Management LPas of 31 Mar 2024 | 7.86m | 8.74% |
| Adage Capital Management LPas of 31 Mar 2024 | 1.82m | 2.03% |
| BVF Partners LPas of 31 Mar 2024 | 1.52m | 1.69% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 1.50m | 1.67% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.28m | 1.43% |
| Polar Capital LLPas of 31 Mar 2024 | 1.25m | 1.39% |
| Millennium Management LLCas of 31 Mar 2024 | 947.53k | 1.05% |
| GMT Capital Corp.as of 31 Mar 2024 | 943.14k | 1.05% |
| Jennison Associates LLCas of 31 Mar 2024 | 930.85k | 1.03% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
